The initial success of Sildenafil undeniably reshaped the drug landscape, but placing funds in companies strongly reliant on generic versions presents a challenging picture. While early profits were significant, the expiration of patents and the appearance of less expensive alternatives have weakened the customer base. Consequently, a thorough eval